Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the primary application of the soft robotic finger in diagnostics by end of 2025?
Pulse checking • 25%
Tissue abnormality detection • 25%
Blood pressure monitoring • 25%
Other • 25%
Medical journals, research publications, or official reports from healthcare institutions
New Soft Robotic Finger from China Enhances Medical Diagnostics
Oct 9, 2024, 11:50 PM
Researchers in China have developed a new soft robotic finger capable of performing medical examinations, including checking patients' pulse and detecting tissue abnormalities. The device, equipped with sensors that mimic human touch, offers potential for improved medical diagnostics. The project, funded by DARPA, aims to enhance the capabilities of medical diagnostics, particularly in low-resource regions.
View original story
Medical devices • 25%
Agricultural technology • 25%
Environmental monitoring • 25%
Other • 25%
Medical Robotics • 25%
Industrial Robotics • 25%
Consumer Robotics • 25%
Military Robotics • 25%
Orthopedic surgery • 25%
Cardiovascular surgery • 25%
Neurosurgery • 25%
General surgery • 25%
Heart surgery • 25%
Kidney transplant • 25%
Liver transplant • 25%
Other • 25%
Forensic Science • 25%
Orthodontics • 25%
Pediatric Dentistry • 25%
General Diagnostics • 25%
Medical Devices • 25%
Robotics • 25%
Consumer Electronics • 25%
Other • 25%
Breast Cancer Diagnosis • 25%
Lung Cancer Diagnosis • 25%
Prostate Cancer Diagnosis • 25%
Other • 25%
Medical Training • 25%
Customer Service • 25%
Entertainment • 25%
Personal Assistance • 25%
Knot tying • 25%
Needle manipulation • 25%
Soft-tissue manipulation • 25%
Other • 25%
Speech restoration • 25%
Motor function restoration • 25%
Sensory restoration • 25%
Other • 25%
Healthcare • 25%
Customer Service • 25%
Entertainment • 25%
Manufacturing • 25%
Enhanced mobility • 25%
Improved sensing capabilities • 25%
Longer operational lifespan • 25%
Other • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Government grants • 25%
Non-profit organizations • 25%
Public companies • 25%
Private investors • 25%